Article

Optical image-guided surgery--where do we stand?

Department of Otorhinolaryngology, Head & Neck Surgery, Erasmus Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
Molecular imaging and biology: MIB: the official publication of the Academy of Molecular Imaging (Impact Factor: 2.47). 04/2011; 13(2):199-207. DOI: 10.1007/s11307-010-0373-2
Source: PubMed

ABSTRACT In cancer surgery, intra-operative assessment of the tumor-free margin, which is critical for the prognosis of the patient, relies on the visual appearance and palpation of the tumor. Optical imaging techniques provide real-time visualization of the tumor, warranting intra-operative image-guided surgery. Within this field, imaging in the near-infrared light spectrum offers two essential advantages: increased tissue penetration of light and an increased signal-to-background-ratio of contrast agents. In this article, we review the various techniques, contrast agents, and camera systems that are currently used for image-guided surgery. Furthermore, we provide an overview of the wide range of molecular contrast agents targeting specific hallmarks of cancer and we describe perspectives on its future use in cancer surgery.

1 Bookmark
 · 
246 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Medical imaging plays a critical role in cancer diagnosis and planning. Many of these patients rely on surgical intervention for curative outcomes. This requires a careful identification of the primary and microscopic tumors, and the complete removal of cancer. Although there have been efforts to adapt traditional-imaging modalities for intraoperative image guidance, they suffer from several constraints such as large hardware footprint, high-operation cost, and disruption of the surgical workflow. Because of the ease of image acquisition, relatively low-cost devices and intuitive operation, optical imaging methods have received tremendous interests for use in real-time image-guided surgery. To improve imaging depth under low interference by tissue autofluorescence, many of these applications utilize light in the near-infrared (NIR) wavelengths, which is invisible to human eyes. With the availability of a wide selection of tumor-avid contrast agents, advancements in imaging sensors, electronic and optical designs, surgeons are able to combine different attributes of NIR optical imaging techniques to improve treatment outcomes. The emergence of diverse commercial and experimental image guidance systems, which are in various stages of clinical translation, attests to the potential high impact of intraoperative optical imaging methods to improve speed of oncologic surgery with high accuracy and minimal margin positivity.
    Advances in cancer research. 01/2014; 124:171-211.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is a major threat to human health. Diagnosis and treatment using precision medicine is expected to be an effective method for preventing the initiation and progression of cancer. Although anatomical and functional imaging techniques such as radiography, computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) have played an important role for accurate preoperative diagnostics, for the most part these techniques cannot be applied intraoperatively. Optical molecular imaging is a promising technique that provides a high degree of sensitivity and specificity in tumor margin detection. Furthermore, existing clinical applications have proven that optical molecular imaging is a powerful intraoperative tool for guiding surgeons performing precision procedures, thus enabling radical resection and improved survival rates. However, detection depth limitation exists in optical molecular imaging methods and further breakthroughs from optical to multi-modality intraoperative imaging methods are needed to develop more extensive and comprehensive intraoperative applications. Here, we review the current intraoperative optical molecular imaging technologies, focusing on contrast agents and surgical navigation systems, and then discuss the future prospects of multi-modality imaging technology for intraoperative imaging-guided cancer surgery.
    Theranostics 01/2014; 4(11):1072-1084. · 7.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Radical removal of malignant lesions may be improved using tumor targeted dual-modality probes that contain both a radiotracer and a fluorescent label, to allow for enhanced intra-operative delineation of tumor resection margins. Since pretargeting strategies yield high signal-to-background ratios, we evaluated the feasibility of a pretargeting strategy for intra-operative imaging in prostate cancer using an anti-TROP-2 x anti-HSG bispecific antibody (TF12), in conjunction with the dual-labeled diHSG peptide (RDC018) equipped with both a DOTA chelate for radiolabeling and a fluorophore (IRdye800CW) for near-infrared fluorescence (NIRF) imaging. Nude mice implanted s.c. with TROP-2-expressing PC3 human prostate tumor cells or with PC3 metastases in the scapular and suprarenal region were injected i.v. with 1 mg of TF12 and, after 16h of tumor accumulation and blood clearance, were subsequently injected with 10 MBq, 0.2 nmol/mouse of either (111)In-RDC018 or (111)In-IMP288 as a control. Two hours p.i., both microSPECT/CT and fluorescence images were acquired, both before and after resection of the tumor nodules. Subsequently, the biodistribution of (111)In-RDC018 and (111)In-IMP288 was determined. The biodistribution of the dual-label RDC018 showed specific accumulation in the TROP-2 expressing PC3 tumors (12.4±3.7% ID/g at 2h p.i.), comparable to (111)In-IMP288 (9.1±2.8% ID/g at 2h p.i.). MicroSPECT/CT and NIRF imaging confirmed this TROP-2-specific uptake of (111)In-RDC018 in both the s.c. and metastatic growing tumor model. In addition, PC3 metastases could be visualized preoperatively with SPECT/CT and could subsequently be resected by image-guided surgery using intra-operative NIRF imaging, showing the preclinical feasibility of the pretargeted dual-modality imaging approach in prostate cancer.
    Cancer Research 09/2014; · 9.28 Impact Factor

Full-text (3 Sources)

Download
65 Downloads
Available from
May 31, 2014